Read post #38. You may say it's too long so here is a summary of it:
Big pharma would love for the myth of HCQ against COVID-19 to continue. Big profits to be had in Africa where the HCQ price has jumped 19 times from $5 to $95. It's the opposite of what you think. Propping up remdesivir, the more expensive alternative, only benefits the small start-up Gilead Sciences, since it's under patent. All the other big pharma companies can make out-of-patent HCQ and sell it for 19 times more than its usual price, in the populous African countries and elsewhere.
Countries around the world are using it - not anymore. They are dropping out of it like flies, as their FDA-equivalents realize that the risks outweigh the benefits.
What the hell are you LOL'ing about? It's safe for malaria and lupus and RA because these diseases don't cause myocarditis so the well-known cardiac toxicity of HCQ (the FDA warning on it was issued in 2007) doesn't affect those patients, while it is not safe for COVID-19 which does cause myocarditis, amplifying the cardiac toxicity problem inherent to HCQ. Insulin is safe and helpful for diabetics, and fatal for non-diabetics (has been even used as a murder weapon before). Safety is always disease-specific.
LOL, your "evidence" is a tweet... which even lists Italy. FYI, Italy's FDA-equivalent has yanked out HCQ.
I don't doubt that there are some stupid countries that haven't caught up to the FACT (as proven by RCTs, not tweets) that HCQ has more risks than benefits in COVID-19 patients, but if their health officials are any good, little by little they will walk away from it, like it is already happening in the advanced and developed countries.